VYNE Therapeutics’ (VYNE) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research note published on Monday morning,Benzinga reports. The firm currently has a $5.75 target price on the stock.

Separately, BTIG Research initiated coverage on VYNE Therapeutics in a research report on Monday, November 18th. They issued a “buy” rating and a $8.00 target price on the stock.

VYNE Therapeutics Trading Up 2.8 %

NASDAQ VYNE opened at $2.57 on Monday. VYNE Therapeutics has a 1-year low of $1.57 and a 1-year high of $3.43. The firm’s fifty day simple moving average is $2.70 and its 200-day simple moving average is $2.20. The company has a market capitalization of $37.91 million, a PE ratio of -2.99 and a beta of 1.37.

Institutional Trading of VYNE Therapeutics

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP bought a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics comprises 0.0% of Lynx1 Capital Management LP’s portfolio, making the stock its 17th largest position. Lynx1 Capital Management LP owned 0.11% of VYNE Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.